{"id":"NCT02099110","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","officialTitle":"A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-22","primaryCompletion":"2016-05-26","completion":"2016-05-26","firstPosted":"2014-03-28","resultsPosted":"2017-11-01","lastUpdate":"2018-09-12"},"enrollment":1233,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Matching Placebo to Ertugliflozin 5 mg","otherNames":[]},{"type":"DRUG","name":"Matching Placebo to Ertugliflozin 10 mg","otherNames":[]},{"type":"DRUG","name":"Matching Placebo to sitagliptin 100 mg","otherNames":[]},{"type":"DRUG","name":"Ertugliflozin 5 mg","otherNames":["MK-8835","PF-04971729"]},{"type":"DRUG","name":"Ertugliflozin 10 mg","otherNames":["MK-8835","PF-04971729"]},{"type":"DRUG","name":"Sitagliptin 100 mg","otherNames":["JANUVIAÂ®"]},{"type":"DRUG","name":"Metformin >= 1500 mg/day","otherNames":["Glucophage","Glucophage XR"]},{"type":"BIOLOGICAL","name":"Insulin Glargine Rescue Medication","otherNames":["Lantus"]},{"type":"DRUG","name":"Glimepiride Rescue Medication","otherNames":["AMARYL"]}],"arms":[{"label":"Ertugliflozin 5 mg + sitagliptin 100 mg","type":"EXPERIMENTAL"},{"label":"Ertugliflozin 15 mg + sitagliptin 100 mg","type":"EXPERIMENTAL"},{"label":"Ertugliflozin 5 mg","type":"EXPERIMENTAL"},{"label":"Ertugliflozin 15 mg","type":"EXPERIMENTAL"},{"label":"Sitagliptin 100 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.","primaryOutcome":{"measure":"Change From Baseline in A1C at Week 26: Excluding Rescue Approach","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Ertugliflozin 5 mg","deltaMin":-1.02,"sd":null},{"arm":"Ertugliflozin 15 mg","deltaMin":-1.08,"sd":null},{"arm":"Sitagliptin 100 mg","deltaMin":-1.05,"sd":null},{"arm":"Ertugliflozin 5 mg + Sitagliptin 100 mg","deltaMin":-1.49,"sd":null},{"arm":"Ertugliflozin 15 mg + Sitagliptin 100 mg","deltaMin":-1.52,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG002 vs OG003","p":"<0.001"},{"comp":"OG001 vs OG004","p":"<0.001"},{"comp":"OG002 vs OG004","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":27},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29266675","34213819","32700393","32648108","32372382","32324082","32324065","31797522"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":250},"commonTop":["Urinary tract infection","Hypoglycaemia","Nasopharyngitis"]}}